Glaxo, Eon Settle Wellbutrin Patent Dispute

Law360 (April 28, 2004, 12:00 AM EDT) -- Drug maker GlaxoSmithKline PLC and generic pharmaceutical company Eon Labs Inc. have settled all patent litigation regarding Eon's Bupropion HCl, ER 100 mg and 10 mg tablets, the two companies said.

Eon's Bupropion drug is the generic equivalent of GlaxoSmithKline's Wellbutrin (bupropion HCl extended- release).

Under terms of the settlement, GlaxoSmithKline has agreed to drop any further effort to pursue its claim that Bupropion HCl, ER 100 mg and 150 mg tablets infringe its patents.

On Nov. 26, the Food and Drug Administration approved Eon’s tablet...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.